https://www.selleckchem.com/products/brd0539.html
rial. This study uses a patient-specific model to characterize and compare ideal PSA kinetics for low- and intermediate-risk prostate cancer following definitive radiation treatment with conventionally fractionated (CFRT), hypofractionated (HFRT), stereotactic body radiation therapy (SbRT), or brachytherapy, both high-dose-rate (HDR) and low-dose-rate (LDR). This retrospective analysis includes low- and intermediate-risk prostate cancer patients treated between 1998 and 2018 at an NCI-designated Comprehensive Cancer Center. Demographics
Like
Comment
Share
